--- title: "What's Going On With Eli Lilly Stock On Tuesday?" description: "Eli Lilly and Co. (LLY) stock fell 4.93% to $768.27 on Tuesday, influenced by Novo Nordisk's reduced 2025 financial outlook for its weight loss drugs. Novo Nordisk lowered its sales growth forecast to" type: "news" locale: "en" url: "https://longbridge.com/en/news/250642202.md" published_at: "2025-07-29T17:03:52.000Z" --- # What's Going On With Eli Lilly Stock On Tuesday? > Eli Lilly and Co. (LLY) stock fell 4.93% to $768.27 on Tuesday, influenced by Novo Nordisk's reduced 2025 financial outlook for its weight loss drugs. Novo Nordisk lowered its sales growth forecast to 8-14% from 13-21%, citing slower market penetration. Additionally, over 80 bipartisan members urged the FDA to combat counterfeit GLP-1 drugs. Eli Lilly also announced positive topline results from its Phase 3 BRUIN CLL-314 trial for Jaypirca (pirtobrutinib) against Imbruvica (ibrutinib) in chronic lymphocytic leukemia, meeting its primary endpoint. **Eli Lilly and Co.** LLY stock is trading lower on Tuesday after its weight loss drug rival, **Novo Nordisk A/S** NVO, trimmed its 2025 financial outlook. The cut marks the second time this year Novo Nordisk has lowered its guidance. Novo Nordisk now projects 2025 sales growth to be 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%. This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives. Trending Investment Opportunities ## GLP-1 Drugs In a letter to the U.S. Food and Drug Administration (FDA) Commissioner **Marty Makary** on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound from flooding the market. The group wrote the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S. The group urged the FDA to issue warning letters, pursue civil enforcement, and monitor non-compliant online retailers and compounding pharmacies selling unapproved weight-loss drugs. In April, after media reports on **Hims & Hers Inc.** HIMS partnering with the company, Eli Lilly said in a statement that it has no affiliation with Hims & Hers. Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as little as $25. ## Trial Data On Tuesday, Eli Lilly also released topline results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). **Johnson & Johnson’s** JNJ Imbruvica is a covalent BTK inhibitor. The study enrolled patients with treatment-naïve CLL/SLL and those previously treated but were BTK inhibitor-naïve. The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations. ORR favored pirtobrutinib with a nominal P-value for superiority (p <0.05). Progression-free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending toward pirtobrutinib. BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients. The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025. These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population. The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally. **Price Action:** LLY stock is down 4.93% at $768.27 at the last check on Tuesday. - ***SoFi Technologies Stock Surges On ‘Exceptional’ Q2 Earnings, Raised Guidance*** *Image Via Shutterstock* ### Related Stocks - [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md) - [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Puzo Michael J 在諾和諾德公司 $NVO 擁有價值 32 萬美元的股票持倉 | Puzo Michael J 在第三季度大幅減持了 Novo Nordisk A/S (NYSE:NVO) 的股份，減少幅度達到 86.9%，目前持有 5,775 股，價值 320,000 美元。其他機構投資者也調整了他們的持倉，True | [Link](https://longbridge.com/en/news/276447697.md) | | 諾和諾德公司董事會提議再次選舉 Lars Rebien Sorensen 擔任主席 | 諾和諾德公司董事會提議重新選舉拉斯·瑞比恩·索倫森為董事長 | [Link](https://longbridge.com/en/news/276440991.md) | | 諾和諾德公司提議任命兩名新的董事會成員 | 丹麥製藥公司諾和諾德公司提議在 3 月 26 日於哥本哈根舉行的年度股東大會上新增三名董事會成員。提議的成員包括海倫娜·薩克森、揚·範·德·温克爾和拉莫娜·塞奎拉。薩克森此前已宣佈辭去 Sobi 的職務以加入諾和諾德。還提議重新選舉董事長拉 | [Link](https://longbridge.com/en/news/276442777.md) | | 諾和諾德公司：將在 Ozempic 和 Wegovy 專利到期時準備好替代產品 - Berlingske | 丹麥製藥公司諾和諾德計劃在其藥物 Ozempic 和 Wegovy 的專利於 2031 年在歐洲和 2032 年在美國到期時，準備好替代藥物。研究負責人馬丁·霍爾斯特·朗格表示，某些臨牀試驗中的候選藥物可能會在 2030 年前提交審批。有關 | [Link](https://longbridge.com/en/news/276314777.md) | | 諾和諾德公司獲得歐洲委員會批准使用更高劑量的 Wegovy 注射劑 | 2026 年 2 月 17 日東部時間上午 9:25（MT Newswires）-- 諾和諾德公司（NVO）週二表示，歐洲委員會已批准 Wegovy 的 7.2 毫克每週一次的維持劑量，適用於肥胖成年人。諾和諾德公司表示，此次批准是基於歐洲 | [Link](https://longbridge.com/en/news/276138110.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.